Mepolizumab therapy in severe asthma – a study of long term efficacy and safety

作者
C Reilly,R Anandavelu,Jen L Marsh,J Sullivan,F O'Riordran,S Cotterill,L White,Adel Hasan Mansur
出处
期刊: 卷期号:: 2734-2734
标识
DOI:10.1183/13993003.congress-2022.2734
摘要

Background: clinical trials demonstrated effectiveness of mepolizumab in treatment of severe eosinophilc asthma, but real world evidence on its longterm outcomes remains limited. Aims: to describe the long-term efficacy and safety of mepolizumab in severe asthma. Methods: patients who had at least one treatment of mepolizumab and follow up data of 2+ years were considered for this study. Clinical and safety outcome were retrieved from the local registry. Results: a total of 66 patients were included [mean age 50 years (range 18-79), 73% females, BMI 32.6±7.3kg/m2, %FEV1 predicted 72.2±22, 59% on maintenance oral corticosteroids (OCS)]. Satisfactory clinical response was observed in 35 (53%) at 12 months, 42 (63.6%) at 18 months, and 41 (62%) at 45months. There was sustained reduction in annual severe exacerbations from 6.7±3.0 to 2.0±2.5 (p <0.001) (figure), and complete wean off maintenance OCS at 45months in 46% patients. Compared to baseline, we observed continued improvement at 45 months in asthma control questionnaire [n=57, 3.35±1.3 vs 2.3±1.4, difference -1.01, p<0.0001), blood eosinophil suppression [n=34, 0.5x109/L (0.35, 0.79) vs 0.04 (0.00, 0.10) p<0.0001], but no change in FeNO [n=17, 52(25.5,98) ppb vs 62 (14.7,105, p=0.5], or FEV1 (data not shown). Of the total stopped treatment (n=25/66), 13/25 (52%) were due to lack of response, and 12/25 (48%) were due to side effects or other causes (e.g. pregnancy). Two patients died from non-mepolizumab/asthma related causes. Conclusion: significant proportion of severe asthma patients had positive sustained response to mepolizumab over follow-up period of 45months. Minority stopped treatment due to lack of response or side effects.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Heyley发布了新的文献求助10
刚刚
刚刚
1秒前
何靖完成签到,获得积分10
1秒前
1秒前
丘比特的应助被碧蓝的元柏采纳,获得10
1秒前
2秒前
美小美发布了新的文献求助10
2秒前
2秒前
2秒前
2秒前
张孟孟完成签到,获得积分10
3秒前
3秒前
molihuakai的应助被Ariels采纳,获得10
3秒前
缥缈一曲发布了新的文献求助10
3秒前
初初初啊发布了新的文献求助10
3秒前
3秒前
1241343948完成签到,获得积分10
4秒前
wxydyd完成签到 ,获得积分10
4秒前
陈俊瑶发布了新的文献求助10
4秒前
4秒前
5秒前
lcj1014发布了新的文献求助10
5秒前
5秒前
Dequelstar发布了新的文献求助10
6秒前
6秒前
6秒前
李健的应助被何靖采纳,获得10
6秒前
6秒前
6秒前
Rowlet发布了新的文献求助10
8秒前
8秒前
脑洞疼的应助被Zhao采纳,获得10
8秒前
畅快远山发布了新的文献求助30
8秒前
8秒前
英吉利25发布了新的文献求助10
9秒前
Kyok11完成签到,获得积分10
9秒前
顾矜的应助被杨好圆采纳,获得30
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170142
求助须知:如何正确求助?哪些是违规求助? 9563136
关于积分的说明 21768635
捐赠科研通 7761603
什么是DOI,文献DOI怎么找? 3430600
关于科研通互助平台的介绍 2554420
邀请新用户注册赠送积分活动 2475330